Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models
about
Targeting SOX2 as a Therapeutic Strategy in GlioblastomaLevel of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells.Prognostic value of histone chaperone FACT subunits expression in breast cancer.Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications.Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells.Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.SSRP1 Cooperates with PARP and XRCC1 to Facilitate Single-Strand DNA Break Repair by Chromatin Priming.
P2860
Q28079501-2F2C3349-6D12-429D-B231-D9555569B1BAQ33591234-BBEA7836-CF77-417D-B17E-D8A71A1F7DE4Q33649913-512F6DC9-AC54-4F85-ADBD-82D2E049ED24Q39218100-9DCCAA70-45EF-4275-92E4-4919FAC82DBCQ42359768-500CC608-4D94-4957-BA79-8301BD4BCBCDQ47877975-FD6CB61F-FDFC-4392-8D63-34A37BA485EAQ48106178-FC12EF53-C898-49B9-B87B-D9B67A3AD640Q48644134-06A9D8CF-380D-4189-9581-F11D0870A637Q50913091-6610889C-AE47-4957-B8D3-29FE4884D8DB
P2860
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pharmacological Targeting of t ...... Survival in Preclinical Models
@en
Pharmacological Targeting of t ...... Survival in Preclinical Models
@nl
type
label
Pharmacological Targeting of t ...... Survival in Preclinical Models
@en
Pharmacological Targeting of t ...... Survival in Preclinical Models
@nl
prefLabel
Pharmacological Targeting of t ...... Survival in Preclinical Models
@en
Pharmacological Targeting of t ...... Survival in Preclinical Models
@nl
P2093
P2860
P1433
P1476
Pharmacological Targeting of t ...... Survival in Preclinical Models
@en
P2093
Andrei A Purmal
Andrew E Sloan
Daniel J Silver
George R Stark
Jeremy N Rich
Josephine Kam Tai Dermawan
Justin D Lathia
Katerina V Gurova
Masahiro Hitomi
Monica Venere
P2860
P304
P356
10.1158/0008-5472.CAN-15-2162
P407
P577
2016-02-26T00:00:00Z